This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
bcg vaccination | 747 |
trained immunity | 309 |
bcg vaccine | 272 |
immune response | 197 |
bacillus calmette | 161 |
universal bcg | 151 |
innate immune | 142 |
immune responses | 132 |
vaccination policy | 126 |
clinical trials | 118 |
mycobacterium tuberculosis | 113 |
immune system | 112 |
per million | 108 |
bacille calmette | 102 |
bladder cancer | 102 |
author funder | 99 |
copyright holder | 99 |
granted medrxiv | 99 |
respiratory syndrome | 95 |
version posted | 94 |
acute respiratory | 92 |
coronavirus disease | 84 |
made available | 82 |
international license | 77 |
mycobacterium bovis | 74 |
severe acute | 72 |
protective effect | 70 |
dendritic cells | 62 |
doc id | 61 |
cord uid | 61 |
syndrome coronavirus | 61 |
lymph nodes | 60 |
immune cells | 60 |
bovis bcg | 60 |
respiratory tract | 58 |
viral infections | 58 |
infectious diseases | 58 |
vaccination policies | 58 |
world health | 57 |
million population | 57 |
innate immunity | 54 |
health organization | 53 |
medrxiv preprint | 52 |
novel coronavirus | 51 |
peer review | 50 |
cell responses | 50 |
systematic review | 48 |
cytokine production | 48 |
severe covid | 48 |
income countries | 48 |
vaccine development | 47 |
mortality rate | 46 |
deaths per | 46 |
health care | 45 |
primary immunodeficiency | 45 |
live attenuated | 45 |
mortality rates | 44 |
bcg coverage | 43 |
bone marrow | 43 |
risk factors | 43 |
gene expression | 43 |
viral infection | 41 |
specific effects | 41 |
inflammatory response | 41 |
induced trained | 41 |
randomized controlled | 41 |
autoimmune diseases | 39 |
total number | 38 |
salmonella enterica | 38 |
clinical trial | 38 |
attenuated salmonella | 37 |
age group | 37 |
inflammatory cytokines | 37 |
tract infections | 37 |
listeria monocytogenes | 36 |
posted may | 36 |
adverse events | 36 |
bcg strains | 36 |
adaptive immune | 35 |
respiratory infections | 35 |
bcg immunization | 35 |
national bcg | 35 |
enterica serovar | 34 |
leprosy patients | 34 |
statistically significant | 33 |
protective immunity | 33 |
years old | 33 |
controlled trial | 33 |
side effects | 33 |
influenza vaccination | 33 |
lymph node | 33 |
epithelial cells | 33 |
bcg administration | 32 |
cases per | 32 |
mg dl | 32 |
virus infection | 32 |
influenza virus | 32 |
united states | 32 |
posted june | 31 |
immunodeficiency virus | 31 |
vaccination coverage | 30 |
south africa | 30 |
combined immunodeficiency | 30 |
epidemiological study | 29 |
cervical lymph | 29 |
nk cells | 29 |
cvid patients | 29 |
controlled trials | 29 |
public health | 29 |
cd cd | 29 |
bcg policy | 29 |
median age | 29 |
increased risk | 29 |
immune memory | 29 |
statistical significance | 28 |
escherichia coli | 28 |
middle east | 28 |
vaccine candidate | 28 |
disease severity | 27 |
tuberculosis infection | 27 |
reduced morbidity | 27 |
helicobacter pylori | 27 |
yellow fever | 27 |
prostate cancer | 27 |
different countries | 27 |
population size | 27 |
intravesical bcg | 27 |
bcg infection | 27 |
antibody responses | 26 |
per capita | 26 |
table i | 26 |
case fatality | 26 |
cohort study | 26 |
human immunodeficiency | 26 |
rights reserved | 25 |
vaccine coverage | 25 |
fatality rate | 25 |
respiratory syncytial | 25 |
guinea pigs | 25 |
flow cytometry | 25 |
bovine lactoferrin | 25 |
tuberculosis vaccine | 25 |
dna vaccine | 25 |
recent study | 25 |
linear regression | 25 |
regression discontinuity | 25 |
syncytial virus | 25 |
coronavirus infection | 24 |
randomized clinical | 24 |
upper respiratory | 24 |
neutralizing antibodies | 24 |
protective effects | 24 |
sars coronavirus | 24 |
primary immunodeficiencies | 23 |
vaccine strains | 23 |
vaccine candidates | 23 |
severe combined | 23 |
high risk | 23 |
million inhabitants | 23 |
nonspecific effects | 23 |
specific cd | 23 |
vaccine efficacy | 23 |
epigenetic reprogramming | 22 |
hematopoietic stem | 22 |
exposure prophylaxis | 22 |
kawasaki disease | 22 |
mediated immunity | 22 |
serovar typhimurium | 22 |
world atlas | 22 |
cell carcinoma | 22 |
born just | 22 |
significantly lower | 22 |
bcg world | 22 |
recombinant bcg | 22 |
care workers | 22 |
leprosy control | 22 |
east respiratory | 22 |
global bcg | 22 |
pid patients | 21 |
household contacts | 21 |
vaccination status | 21 |
tca cycle | 21 |
family history | 21 |
peripheral blood | 21 |
single dose | 21 |
salmonella typhimurium | 21 |
invasive bladder | 21 |
production capacity | 21 |
healthcare workers | 21 |
chronic granulomatous | 21 |
age groups | 21 |
adult patients | 20 |
million people | 20 |
animal models | 20 |
memory cd | 20 |
th th | 20 |
mouse model | 20 |
ex vivo | 20 |
intensive care | 20 |
natural killer | 20 |
antibody response | 20 |
human monocytes | 20 |
alveolar macrophages | 20 |
bcg reactivation | 20 |
bcg vaccines | 20 |
vaccination protects | 20 |
infectious disease | 20 |
high levels | 20 |
cell immunity | 20 |
granulomatous disease | 20 |
th responses | 20 |
cell surface | 19 |
experimental viral | 19 |
bcg countries | 19 |
mediated immune | 19 |
urothelial carcinoma | 19 |
factors associated | 19 |
autoimmune disease | 19 |
case report | 19 |
related complications | 19 |
past years | 19 |
two groups | 19 |
stem cell | 19 |
inflammatory responses | 19 |
presenting cells | 19 |
vaccine vector | 19 |
cytokine expression | 19 |
per inhabitants | 19 |
among patients | 19 |
spike protein | 18 |
cancer patients | 18 |
recurrent infections | 18 |
vaccine strain | 18 |
previous studies | 18 |
based vaccines | 18 |
vaccination program | 18 |
replacement therapy | 18 |
metabolic pathways | 18 |
like receptor | 18 |
adherent cells | 18 |
three months | 18 |
available data | 18 |
trained innate | 18 |
rheumatoid arthritis | 18 |
cohorts born | 18 |
across countries | 17 |
cytokines associated | 17 |
superficial bladder | 17 |
clinical features | 17 |
cytokine storm | 17 |
may also | 17 |
mice infected | 17 |
immune reconstitution | 17 |
class ii | 17 |
severe disease | 17 |
antibody deficiency | 17 |
protein kinase | 17 |
dna vaccines | 17 |
lupus erythematosus | 17 |
important role | 17 |
human lactoferrin | 17 |
protective efficacy | 17 |
infectious agents | 17 |
cd cells | 17 |
renal cell | 17 |
viral load | 17 |
data suggest | 17 |
fatality rates | 17 |
healthy volunteers | 17 |
clinical characteristics | 17 |
bacterial vectors | 17 |
murine model | 17 |
influenza vaccine | 17 |
lower respiratory | 16 |
social distancing | 16 |
many countries | 16 |
nonspecific protection | 16 |
clinical immunology | 16 |
infected cells | 16 |
systemic lupus | 16 |
even though | 16 |
randomised controlled | 16 |
disseminated bcg | 16 |
standard deviation | 16 |
amino acid | 16 |
binding domain | 16 |
vaccination programs | 16 |
physical examination | 16 |
lower mortality | 16 |
confounding factors | 16 |
cell types | 16 |
vaccine antigens | 16 |
total population | 16 |
high prevalence | 16 |
fatty acid | 16 |
antiviral activity | 16 |
population density | 16 |
inflammatory syndrome | 16 |
randomized trial | 16 |
first year | 16 |
environmental factors | 16 |
necrosis factor | 16 |
secretion system | 15 |
high income | 15 |
inoculation site | 15 |
reported cases | 15 |
host cells | 15 |
bcg immunisation | 15 |
nitric oxide | 15 |
respiratory distress | 15 |
antibody deficiencies | 15 |
tissue damage | 15 |
significant difference | 15 |
molecular patterns | 15 |
vaccinated subjects | 15 |
convalescent plasma | 15 |
mg ml | 15 |
current universal | 15 |
cell wall | 15 |
bcg strain | 15 |
authors declare | 15 |
adaptive immunity | 15 |
bacterial infections | 15 |
mycobacterial infection | 15 |
immunodeficiency diseases | 14 |
medical history | 14 |
one study | 14 |
cardiovascular disease | 14 |
european countries | 14 |
health system | 14 |
immune cell | 14 |
nan doi | 14 |
cell activation | 14 |
virulence factors | 14 |
bcg inoculation | 14 |
higher mortality | 14 |
without permission | 14 |
scid patients | 14 |
cell transplantation | 14 |
healthy individuals | 14 |
recent bcg | 14 |
attributable mortality | 14 |
candida albicans | 14 |
ecological studies | 14 |
causal reasoning | 14 |
childhood vaccination | 14 |
autosomal recessive | 14 |
african countries | 14 |
cell populations | 14 |
statistical analysis | 14 |
immunity effects | 14 |
epigenetic changes | 14 |
dose rifampicin | 14 |
stem cells | 14 |
common variable | 14 |
case reports | 14 |
cell function | 14 |
neutralizing antibody | 14 |
risk disease | 14 |
confidence interval | 14 |
associated molecular | 14 |
vaccination rate | 14 |
bcg induced | 14 |
new york | 14 |
allowed without | 14 |
reuse allowed | 14 |
risk factor | 14 |
node cells | 14 |
based vaccine | 14 |
study showed | 14 |
gov identifier | 14 |
lung injury | 13 |
old boy | 13 |
new coronavirus | 13 |
bcg induces | 13 |
distress syndrome | 13 |
mortality per | 13 |
rhesus macaques | 13 |
received bcg | 13 |
cell cultures | 13 |
time point | 13 |
bcg vaccinated | 13 |
hiv infection | 13 |
correlation hypothesis | 13 |
clinical manifestations | 13 |
oral vaccine | 13 |
attenuated vaccine | 13 |
recombinant human | 13 |
hbv vaccine | 13 |
mm nacl | 13 |
specific memory | 13 |
present study | 13 |
beneficial effects | 13 |
lasting effects | 13 |
heat killed | 13 |
like receptors | 13 |
young adults | 13 |
ivig therapy | 13 |
past medical | 13 |
six months | 13 |
reduced covid | 13 |
attenuated strain | 13 |
world bank | 13 |
antigen presentation | 13 |
tb prevalence | 13 |
publicly available | 13 |
higher risk | 13 |
highly significant | 13 |
tract infection | 13 |
older individuals | 13 |
antigen presenting | 13 |
clinical studies | 13 |
severe infections | 13 |
bcg may | 13 |
vaccine design | 13 |
phase iii | 13 |
post vaccination | 13 |
omenn syndrome | 13 |
new leprosy | 13 |
epidemiological studies | 12 |
vaccination may | 12 |
case detection | 12 |
subunit vaccines | 12 |
young age | 12 |
alignment date | 12 |
com scientificreports | 12 |
cov infection | 12 |
patients diagnosed | 12 |
measles virus | 12 |
posted september | 12 |
bcg mimics | 12 |
old girl | 12 |
salmonella typhi | 12 |
tumor necrosis | 12 |
university hospital | 12 |
time points | 12 |
antiretroviral therapy | 12 |
adverse reactions | 12 |
confidence intervals | 12 |
cytokine responses | 12 |
marrow transplantation | 12 |
two patients | 12 |
tests per | 12 |
mycobacterial disease | 12 |
lactococcus lactis | 12 |
igg subclass | 12 |
several studies | 12 |
salmonella vaccine | 12 |
corynebacterium parvum | 12 |
oral immunization | 12 |
binding protein | 12 |
whole blood | 12 |
heat shock | 12 |
lpep program | 12 |
adverse effects | 12 |
key hubs | 12 |
increased production | 12 |
streptococcus pneumoniae | 12 |
patients receiving | 12 |
diagnostic tests | 12 |
offer protection | 12 |
pilot study | 12 |
disease progression | 12 |
widely used | 12 |
mg kg | 12 |
control group | 12 |
null hypothesis | 12 |
protective role | 12 |
lung tissue | 12 |
global health | 12 |
cell response | 12 |
clinical outcomes | 12 |
vaccine program | 12 |
pseudomonas aeruginosa | 12 |
colep study | 12 |
humoral immune | 12 |
patients treated | 12 |
intravesical therapy | 12 |
host defense | 12 |
control study | 12 |
type i | 12 |
low income | 12 |
genomic dna | 12 |
performed using | 12 |
neonatal period | 12 |
calmette guerin | 12 |
another study | 12 |
connective tissue | 11 |
reduced mortality | 11 |
propionibacterium acnes | 11 |
heterologous th | 11 |
infections per | 11 |
human papillomavirus | 11 |
mm hepes | 11 |
countries without | 11 |
mm cacl | 11 |
unrelated pathogens | 11 |
confirmed cases | 11 |
significant factors | 11 |
trained immune | 11 |
scatter plot | 11 |
via epigenetic | 11 |
mean age | 11 |
current evidence | 11 |
common logarithm | 11 |
data analysis | 11 |
significantly higher | 11 |
negative correlation | 11 |
ivig treatment | 11 |
heterogeneous immunity | 11 |
pulmonary disease | 11 |
adherent fraction | 11 |
april st | 11 |
stimulation index | 11 |
beneficial effect | 11 |
strong correlation | 11 |
acute upper | 11 |
severe respiratory | 11 |
metastatic renal | 11 |
life expectancy | 11 |
clinical presentation | 11 |
dendritic cell | 11 |
also found | 11 |
vaccinia virus | 11 |
observational studies | 11 |
bcg revaccination | 11 |
innate trained | 11 |
variable immunodeficiency | 11 |
bcg therapy | 11 |
general population | 11 |
indian population | 11 |
laboratory findings | 11 |
individuals born | 11 |
syndrome induced | 11 |
measles infection | 11 |
tetanus toxoid | 11 |
mycobacterial antigens | 11 |
bcg expressing | 11 |
significant differences | 11 |
coverage rate | 11 |
type immune | 11 |
upper middle | 11 |
attenuated bacterial | 11 |
natural experiment | 11 |
activated protein | 11 |
class i | 11 |
multiple sclerosis | 11 |
fusion protein | 11 |
dependent enhancement | 10 |
multivariable analysis | 10 |
patients hospitalized | 10 |
chronic inflammatory | 10 |
locally advanced | 10 |
reinfection via | 10 |
lg ml | 10 |
bovis bacillus | 10 |
biochemical recurrence | 10 |
cancer immunotherapy | 10 |
live bcg | 10 |
developing countries | 10 |
different strains | 10 |
year follow | 10 |
cell counts | 10 |
radical prostatectomy | 10 |
whose equation | 10 |
non specific | 10 |
vaccine safety | 10 |
months post | 10 |
middle age | 10 |
hospitalized patients | 10 |
adjuvant effect | 10 |
serovar typhi | 10 |
environmental mycobacteria | 10 |
kidney cancer | 10 |
disease burden | 10 |
protective action | 10 |
new vaccine | 10 |
inflammatory cytokine | 10 |
progenitor cells | 10 |
lung disease | 10 |
studies suggest | 10 |
care unit | 10 |
asia syndrome | 10 |
significant association | 10 |
closely related | 10 |
vaccination enhances | 10 |
tract urothelial | 10 |
acid synthesis | 10 |
critical role | 10 |
seasonal influenza | 10 |
may lead | 10 |
clinical course | 10 |
infected individuals | 10 |
early stages | 10 |
protective immune | 10 |
heterologous effects | 10 |
urgent need | 10 |
immunological memory | 10 |
model whose | 10 |
regression model | 10 |
first time | 10 |
virus type | 10 |
human coronaviruses | 10 |
vaccine delivery | 10 |
regression analysis | 10 |
mass bcg | 10 |
growth factor | 10 |
knockout mutants | 10 |
phase clinical | 10 |
limited number | 10 |
herpes simplex | 10 |
high level | 10 |
ebola virus | 10 |
one year | 10 |
di george | 10 |
immune function | 10 |
last years | 10 |
vaccine vectors | 10 |
tb vaccine | 10 |
mhc class | 10 |
mycobacterial infections | 10 |
described previously | 10 |
converting enzyme | 10 |
active cases | 10 |
viral replication | 10 |
hiv vaccine | 10 |
modified vaccinia | 10 |
new cases | 10 |
determine whether | 9 |
spike glycoprotein | 9 |
suppressor cells | 9 |
discontinuity design | 9 |
mucosal immune | 9 |
oral administration | 9 |
whether bcg | 9 |
heterologous pathogens | 9 |
highly attenuated | 9 |
family members | 9 |
coronavirus vaccines | 9 |
contact tracing | 9 |
induce trained | 9 |
beneficial nonspecific | 9 |
considering bcg | 9 |
cell lines | 9 |
survival outcomes | 9 |
human immune | 9 |
host immune | 9 |
recognition receptors | 9 |
attenuated vaccines | 9 |
mycobacterium leprae | 9 |
bcg use | 9 |
death reports | 9 |
based case | 9 |
acute lung | 9 |
patients showed | 9 |
dependent nonspecific | 9 |
recurrent respiratory | 9 |
narrative review | 9 |
discontinuity designs | 9 |
serine protease | 9 |
positive effect | 9 |
binding site | 9 |
th response | 9 |
diabetes mellitus | 9 |
genetic analysis | 9 |
viral vector | 9 |
unvaccinated young | 9 |
significant associations | 9 |
positive correlation | 9 |
active surveillance | 9 |
bcg vaccinations | 9 |
also known | 9 |
contact screening | 9 |
using bcg | 9 |
birth cohorts | 9 |
mmr vaccine | 9 |
analysis revealed | 9 |
celiac disease | 9 |
leprosy prevention | 9 |
shock protein | 9 |
gene signature | 9 |
induces nod | 9 |
ecological study | 9 |
individuals infected | 9 |
global pandemic | 9 |
respiratory disease | 9 |
phase ii | 9 |
pneumococcal vaccination | 9 |
autoimmune inflammatory | 9 |
programmed death | 9 |
leprosy chemoprophylaxis | 9 |
lower levels | 9 |
type diabetes | 9 |
old friends | 9 |
gastrointestinal tract | 9 |
viral rna | 9 |
specific effect | 9 |
draining lymph | 9 |
urinary tract | 9 |
muramyl dipeptide | 9 |
production following | 9 |
infected macrophages | 9 |
vaccinated group | 9 |
staphylococcus aureus | 9 |
universal vaccination | 9 |
aids vaccine | 9 |
following vaccination | 9 |
patients infected | 9 |
proinflammatory cytokines | 9 |
monoclonal antibodies | 9 |
specific protection | 9 |
epidemiological impact | 9 |
death due | 9 |
also reported | 9 |
protease inhibitor | 9 |
significant correlation | 9 |
vaccine administration | 9 |
innate cells | 9 |
vaccine expressing | 9 |
south korea | 9 |
provided protection | 9 |
odds ratio | 9 |
subsequent influenza | 9 |
months old | 9 |
following influenza | 9 |
hospital admission | 9 |
neoadjuvant adt | 9 |
high incidence | 9 |
mammary gland | 9 |
cell deficiency | 9 |
bcg immunotherapy | 9 |
viral clearance | 9 |
bacillus subtilis | 9 |
immunization program | 9 |
mucocutaneous candidiasis | 9 |
results suggest | 9 |
results showed | 9 |
trained macrophages | 9 |
host cell | 9 |
may result | 9 |
membrane fusion | 9 |
inflammatory mediators | 9 |
prevent leprosy | 9 |
delayed intervention | 9 |
fever virus | 9 |
penile cancer | 9 |
immune deficiency | 9 |
deficient mice | 8 |
deficient patients | 8 |
age years | 8 |
risk groups | 8 |
release syndrome | 8 |
two different | 8 |
nw adherent | 8 |
vaccination strategies | 8 |
several factors | 8 |
guerin induces | 8 |
among bcg | 8 |
pediatric patients | 8 |
immune phenotype | 8 |
vaccine use | 8 |
virulence genes | 8 |
guerin vaccinations | 8 |
may help | 8 |
killer cell | 8 |
old age | 8 |
attenuated listeria | 8 |
inflammatory diseases | 8 |
bcg policies | 8 |
guinea pig | 8 |
coronavirus infections | 8 |
immunocompromised patients | 8 |
recombinant mycobacterium | 8 |
leprosy post | 8 |
subclass deficiency | 8 |
rotavirus infection | 8 |
among individuals | 8 |
study suggests | 8 |
experimental model | 8 |
cellular responses | 8 |
van der | 8 |
different types | 8 |
renal masses | 8 |
polynomial growth | 8 |
tests performed | 8 |
genome sequence | 8 |
united kingdom | 8 |
lower covid | 8 |
rank correlation | 8 |
tlr agonists | 8 |
tuberculosis knockout | 8 |
immune suppression | 8 |
mortality attributed | 8 |
relatively low | 8 |
cell defects | 8 |
clinical symptoms | 8 |
high mortality | 8 |
primary infection | 8 |
live vaccine | 8 |
clinical study | 8 |
exponential growth | 8 |
may protect | 8 |
posted august | 8 |
systemic therapy | 8 |
close contacts | 8 |
induced mkp | 8 |
large number | 8 |
less likely | 8 |
primary antibody | 8 |
immunological examination | 8 |
salmonella infection | 8 |
bcg scar | 8 |
retrospective analysis | 8 |
congenital heart | 8 |
specific mortality | 8 |
new tb | 8 |
mononuclear cells | 8 |
pep administration | 8 |
induces trained | 8 |
signaling pathways | 8 |
immunoglobulin replacement | 8 |
middle high | 8 |
phase trial | 8 |
healthy subjects | 8 |
european association | 8 |
april th | 8 |
cytokine response | 8 |
weight children | 8 |
well known | 8 |
antigen synthesis | 8 |
lamina propria | 8 |
recent vaccination | 8 |
boost vaccination | 8 |
drug administration | 8 |
potential impact | 8 |
immunity induced | 8 |
treat effects | 8 |
findings suggest | 8 |
pharmacological inhibition | 8 |
stat phosphorylation | 8 |
different time | 8 |
immunization policies | 8 |
death rates | 8 |
leukocytoclastic vasculitis | 8 |
cellular immune | 8 |
year old | 8 |
elderly population | 8 |
mrna expression | 8 |
strong association | 8 |
care systems | 8 |
histone modifications | 8 |
may provide | 8 |
trained cells | 8 |
pattern recognition | 8 |
muscle invasive | 8 |
phop mutant | 8 |
cell membrane | 8 |
mucosal surfaces | 8 |
small intestine | 8 |
implementing sdr | 8 |
infections caused | 8 |
explanatory variables | 8 |
vaccination score | 8 |
significantly reduced | 8 |
controlled pilot | 8 |
recent reports | 8 |
th immune | 8 |
type iii | 8 |
viral loads | 8 |
balanced lethal | 8 |
countries like | 8 |
intradermal bcg | 8 |
swedish population | 8 |
modelling study | 8 |
human volunteers | 8 |
provide protection | 8 |
phase i | 8 |
increased cytokine | 8 |
years ago | 8 |
cellular immunity | 8 |
phosphate dehydrogenase | 8 |
sanger sequencing | 8 |
bronchoalveolar lavage | 8 |
disease control | 8 |
iii secretion | 8 |
chain reaction | 8 |
transcriptional changes | 8 |
vaccine protection | 8 |
bcg treatment | 8 |
time since | 8 |
killer cells | 8 |
specific vaccine | 8 |
south african | 8 |
post alignment | 8 |
fungal infections | 8 |
tissue disease | 8 |
older age | 8 |
intestinal epithelial | 8 |
stage i | 8 |
population structure | 8 |
polymerase chain | 8 |
springer nature | 8 |
recovered patients | 8 |
retrospective cohort | 8 |
tuberculous meningitis | 8 |
natural infection | 8 |
cytokine release | 8 |
systematic reviews | 8 |
virus infections | 8 |
key role | 8 |
vaccination reduces | 8 |
live vector | 8 |
nervous system | 8 |
web site | 7 |
strain cvd | 7 |
targeted therapies | 7 |
trough levels | 7 |
confirmed measles | 7 |
entamoeba histolytica | 7 |
latent tb | 7 |
eligibility threshold | 7 |
epidemiological data | 7 |
population may | 7 |
corona viruses | 7 |
mortality among | 7 |
positive control | 7 |
supplementary table | 7 |
specific antibodies | 7 |
mucosal immunity | 7 |
testing capacity | 7 |
developed countries | 7 |
may play | 7 |
recent years | 7 |
plasmid dna | 7 |
york city | 7 |
studies assessing | 7 |
pylori infection | 7 |
estimated using | 7 |
risk populations | 7 |
immunol doi | 7 |
strain expressing | 7 |
shown using | 7 |
two weeks | 7 |
antimicrobial activity | 7 |
vaccine induces | 7 |
leprosy research | 7 |
prospective clinical | 7 |
transcription factors | 7 |
therapeutic options | 7 |
cell death | 7 |
wide range | 7 |
naked dna | 7 |
tb infections | 7 |
disease patients | 7 |
cells also | 7 |
infected patients | 7 |
low levels | 7 |
also showed | 7 |
transcription factor | 7 |
ethnic groups | 7 |
pnp deficiency | 7 |
low cd | 7 |
creative commons | 7 |
several countries | 7 |
chronic fatigue | 7 |
calculate rho | 7 |
type hypersensitivity | 7 |
post auricular | 7 |
mortality due | 7 |
effective vaccine | 7 |
clinical findings | 7 |
fully understood | 7 |
hyper igm | 7 |
patients received | 7 |
recombinant bacillus | 7 |
universal policy | 7 |
respiratory burst | 7 |
acute infection | 7 |
older people | 7 |
severe coronavirus | 7 |
leukocyte antigen | 7 |
using three | 7 |
five years | 7 |
food allergy | 7 |
without bcg | 7 |
specific protective | 7 |
epigenetic enzymes | 7 |
indian sars | 7 |
significant effect | 7 |
resulting effect | 7 |
molecular mimicry | 7 |
critically ill | 7 |
may reduce | 7 |
federated states | 7 |
immunological disorders | 7 |
skin lesions | 7 |
simian immunodeficiency | 7 |
intravenous bcg | 7 |
radical cystectomy | 7 |
month old | 7 |
glucan trained | 7 |
institutional affiliations | 7 |
current pandemic | 7 |
time period | 7 |
mucosal sites | 7 |
letter country | 7 |
immunomodulatory effects | 7 |
early diagnosis | 7 |
since bcg | 7 |
disease caused | 7 |
reconstitution inflammatory | 7 |
cell mediated | 7 |
current covid | 7 |
days post | 7 |
took place | 7 |
including bcg | 7 |
previously described | 7 |
significant reduction | 7 |
nature remains | 7 |
molecular mechanisms | 7 |
might also | 7 |
autoimmune disorders | 7 |
tb infection | 7 |
see table | 7 |
ii deficiency | 7 |
skin infections | 7 |
vitro assays | 7 |
gulf war | 7 |
antimycobacterial treatment | 7 |
myeloid cells | 7 |
liver function | 7 |
increased il | 7 |
effective treatment | 7 |
staphylococcal mastitis | 7 |
two cases | 7 |
barr virus | 7 |
regulated delayed | 7 |
positive connections | 7 |
remains neutral | 7 |
recombinant attenuated | 7 |
later stages | 7 |
immodulon therapeutics | 7 |
around april | 7 |
systems biology | 7 |
following bcg | 7 |
viral entry | 7 |
receptor binding | 7 |
death rate | 7 |
mammalian cells | 7 |
countries according | 7 |
demonstrated increased | 7 |
one week | 7 |
confer protection | 7 |
target effects | 7 |
vaccination scores | 7 |
positive cases | 7 |
west germany | 7 |
among others | 7 |
infant mortality | 7 |
intravenous immunoglobulin | 7 |
efficacy trials | 7 |
childhood mortality | 7 |
clinical research | 7 |
vibrio cholerae | 7 |
virus vaccine | 7 |
influenza vaccines | 7 |
two months | 7 |
high confidence | 7 |
superior protection | 7 |
clinical use | 7 |
mandatory immunization | 7 |
therapeutics ltd | 7 |
transplant bcgosis | 7 |
using countries | 7 |
surface expression | 7 |
test results | 7 |
vector vaccines | 7 |
exclusion criteria | 7 |
combined immunodeficiencies | 7 |
posted march | 7 |
eluted fractions | 7 |
induced protection | 7 |
higher prevalence | 7 |
enhanced cytokine | 7 |
first case | 7 |
birth weight | 7 |
immune mechanisms | 7 |
gross domestic | 7 |
country codes | 7 |
infected mice | 7 |
human leukocyte | 7 |
yersinia pestis | 7 |
injected animals | 7 |
phagocytic cells | 7 |
disorder characterized | 7 |
active tuberculosis | 7 |
neonatal bcg | 7 |
pam cys | 7 |
mucosal iga | 7 |
vaccine strategies | 7 |
higher bcg | 7 |
miliary tuberculosis | 7 |
antigen expression | 7 |
major histocompatibility | 7 |
jurisdictional claims | 7 |
published maps | 7 |
polio vaccine | 7 |
mm edta | 7 |
may offer | 7 |
th cells | 7 |
viral pathogens | 7 |
mycobacterium obuense | 7 |
two variables | 6 |
mucosal delivery | 6 |
flattened curves | 6 |
target cells | 6 |
population share | 6 |
preventing covid | 6 |
medical center | 6 |
bcg delivery | 6 |
herpes zoster | 6 |
test positivity | 6 |
national immunization | 6 |
normal distribution | 6 |
rcts will | 6 |
ct scan | 6 |
significant effects | 6 |
vaccinated population | 6 |
induced cross | 6 |
obstructive pulmonary | 6 |
therapeutic action | 6 |
lethal system | 6 |
possible role | 6 |
lactoferrin protects | 6 |
genes encoding | 6 |
coronavirus covid | 6 |
cd hla | 6 |
isotype control | 6 |
george syndrome | 6 |
antibiotic therapy | 6 |
aged years | 6 |
different vaccines | 6 |
cases reported | 6 |
tb genome | 6 |
broad range | 6 |
less affected | 6 |
severely affected | 6 |
leprosy vaccine | 6 |
granuloma formation | 6 |
also induce | 6 |
born residents | 6 |
coverage rates | 6 |
four patients | 6 |
host defence | 6 |
workers absenteeism | 6 |
bullous pemphigoid | 6 |
higher incidence | 6 |
human peripheral | 6 |
negative association | 6 |
oral polio | 6 |
cell entry | 6 |
outpatient clinic | 6 |
early phase | 6 |
targeted therapy | 6 |
immune activation | 6 |
leprosy cases | 6 |
measles vaccine | 6 |
vector vaccine | 6 |
pathogenic bacteria | 6 |
healthy controls | 6 |
chronic inflammation | 6 |
national health | 6 |
chronic obstructive | 6 |
bcg programs | 6 |
intravesical bacillus | 6 |
rna polymerase | 6 |
sample size | 6 |
vaccines may | 6 |
female patient | 6 |
child survival | 6 |
vaccine trials | 6 |
high precision | 6 |
atopic dermatitis | 6 |
protein antigens | 6 |
intradermal administration | 6 |
additional data | 6 |
pathogenic microbes | 6 |
old female | 6 |
cgd patients | 6 |
energy production | 6 |
central nervous | 6 |
also suggested | 6 |
early bcg | 6 |
biomedical literature | 6 |
immunity benefits | 6 |
simplex virus | 6 |
vaccinated countries | 6 |
real time | 6 |
without universal | 6 |
world population | 6 |
transmission dynamics | 6 |
increasing age | 6 |
vaccination predicts | 6 |
taken together | 6 |
blood mononuclear | 6 |
primary immune | 6 |
gaussian function | 6 |
heterologous prime | 6 |
higher percentage | 6 |
augmented cytokine | 6 |
positive connection | 6 |
igm level | 6 |
including covid | 6 |
protect healthcare | 6 |
mortality associated | 6 |
igm levels | 6 |
human blood | 6 |
tumor cells | 6 |
complete medium | 6 |
lung damage | 6 |
greater risk | 6 |
randomized trials | 6 |
patient care | 6 |
safety profile | 6 |
testicular cancer | 6 |
oral delivery | 6 |
mw vaccine | 6 |
bovis bacille | 6 |
policies tend | 6 |
histocompatibility complex | 6 |
preliminary data | 6 |
many patients | 6 |
differentially expressed | 6 |
immunoglobulin levels | 6 |
provides protection | 6 |
bcg might | 6 |
rapid review | 6 |
two siblings | 6 |
nadph oxidase | 6 |
control programs | 6 |
schnitzler syndrome | 6 |
clinical condition | 6 |
intradermal injection | 6 |
oxidative phosphorylation | 6 |
epigenetic modifications | 6 |
urgently needed | 6 |
respiratory failure | 6 |
strongly correlated | 6 |
mandated bacillus | 6 |
cell receptor | 6 |
wide spectrum | 6 |
young population | 6 |
newborns bcg | 6 |
pa lymph | 6 |
highly specific | 6 |
predicts flattened | 6 |
rna viruses | 6 |
epigenetic programs | 6 |
published literature | 6 |
significant results | 6 |
recently vaccinated | 6 |
murine models | 6 |
term efficacy | 6 |
currently follow | 6 |
will also | 6 |
urothelial cancer | 6 |
oxygen species | 6 |
live vaccines | 6 |
recent universal | 6 |
aerobic glycolysis | 6 |
four months | 6 |
human cell | 6 |
death toll | 6 |
vaccination might | 6 |
mdp concentration | 6 |
lymphocyte subsets | 6 |
university medical | 6 |
open resources | 6 |
income group | 6 |
primary human | 6 |
among countries | 6 |
track covid | 6 |
within normal | 6 |
error bars | 6 |
disease course | 6 |
future studies | 6 |
clinical hospital | 6 |
recent studies | 6 |
deaths due | 6 |
enterotoxigenic escherichia | 6 |
immunological response | 6 |
ige syndrome | 6 |
bcg substrains | 6 |
malignant melanoma | 6 |
bcg alone | 6 |
affinity chromatography | 6 |
influenza viruses | 6 |
termed trained | 6 |
low igg | 6 |
vaccinated patients | 6 |
large population | 6 |
genetic defects | 6 |
disease status | 6 |
leprosy transmission | 6 |
reported deaths | 6 |
rd index | 6 |
beneficial non | 6 |
acid sequence | 6 |
effector memory | 6 |
bcg protection | 6 |
daily cases | 6 |
nylon wool | 6 |
hospitalization rate | 6 |
urology guidelines | 6 |
similar results | 6 |
subunit vaccine | 6 |
incubation period | 6 |
igg mg | 6 |
treatment effect | 6 |
mandatory bcg | 6 |
heart disease | 6 |
may present | 6 |
domestic product | 6 |
population level | 6 |
induced cytokine | 6 |
trained monocytes | 6 |
cell line | 6 |
saharan africa | 6 |
vaccination also | 6 |
leprosy patient | 6 |
children aged | 6 |
mycobacterial growth | 6 |
close contact | 6 |
igm syndrome | 6 |
antibody tests | 6 |
based dashboard | 6 |
total cholesterol | 6 |
androgen deprivation | 6 |
leprosy incidence | 6 |
ill patients | 6 |
respiratory viruses | 6 |
pregnant women | 6 |
also significant | 6 |
clinical disease | 6 |
interactive web | 6 |
salmonella strains | 6 |
cell subsets | 6 |
single center | 6 |
endothelial cells | 6 |
newly diagnosed | 6 |
literature review | 6 |
well established | 6 |
massive bcg | 6 |
cell differentiation | 6 |
humoral immunity | 6 |
working group | 6 |
igg levels | 6 |
high rate | 6 |
blf administration | 6 |
mendelian susceptibility | 6 |
blood vessels | 6 |
several years | 6 |
coronavirus vaccine | 6 |
pathogens including | 6 |
antibiotic resistance | 6 |
health observatory | 6 |
reducing health | 6 |
innate memory | 6 |
respiratory pathogens | 6 |
two major | 6 |
one patient | 6 |
sign binding | 6 |
gene encoding | 6 |
dengue virus | 6 |
shigella flexneri | 6 |
inflammatory processes | 6 |
throat swab | 6 |
tb vaccines | 6 |
wasp gene | 6 |
patients without | 6 |
three age | 6 |
immune dysregulation | 6 |
potential role | 6 |
surfactant protein | 6 |
upper tract | 6 |
clinical data | 6 |
systemic immune | 6 |
patients may | 6 |
testing rates | 6 |
vaccine may | 6 |
neonatal sepsis | 6 |
including sars | 6 |
chronic lung | 6 |
protein expression | 6 |
scientificreports www | 6 |
statistical precision | 6 |
bp deletion | 6 |
serious adverse | 6 |
per population | 6 |
killed mycobacterium | 6 |
human primates | 6 |
immunomodulatory properties | 6 |
aldrich syndrome | 6 |
acute lower | 6 |
quarterly birth | 6 |
reactive oxygen | 6 |
overall mortality | 6 |
tuberculosis vaccines | 6 |
critical importance | 6 |
western blot | 6 |
immunity might | 6 |
human primary | 6 |
assess whether | 6 |
small molecule | 6 |
infections including | 6 |
stat activation | 6 |
linked glycosylation | 6 |
blf treatment | 6 |
currently underway | 6 |
distancing measures | 6 |
specific th | 5 |
experimental studies | 5 |
epidermal growth | 5 |
nuclear factor | 5 |
trials will | 5 |
cellular components | 5 |
patients requiring | 5 |
male patient | 5 |
many years | 5 |
cord blood | 5 |
note springer | 5 |
interquartile range | 5 |
east germany | 5 |
lower number | 5 |
wheezing attacks | 5 |
blood monocytes | 5 |
immunodeficiency disorders | 5 |
proinflammatory cytokine | 5 |
consensus gene | 5 |
bcg prime | 5 |
immunodeficiency disorder | 5 |
th day | 5 |
lockdown measures | 5 |
ventricular arrhythmia | 5 |
therapeutic effects | 5 |
intestinal inflammation | 5 |
colleagues found | 5 |
including tnf | 5 |
extension study | 5 |
may influence | 5 |
fever vaccine | 5 |
selected country | 5 |
one month | 5 |
immunosuppressed patients | 5 |
mammalian hosts | 5 |
cd deficiency | 5 |
adjuvanted vaccine | 5 |
phosphate pathway | 5 |
universal policies | 5 |
strong protective | 5 |
prophylactic treatment | 5 |
room temperature | 5 |
peritonitis virus | 5 |
increased levels | 5 |
test number | 5 |
higher levels | 5 |
curative treatment | 5 |
oncologic outcomes | 5 |
medical school | 5 |
infection bcg | 5 |
risk pca | 5 |
heterologous stimulation | 5 |
underwent hsct | 5 |
eau guidelines | 5 |
remains unknown | 5 |
will probably | 5 |
leprosy contacts | 5 |
enhanced protection | 5 |
differential effects | 5 |
sinopulmonary infections | 5 |
iu ml | 5 |
connectivity scores | 5 |
heterologous immunity | 5 |
last months | 5 |
rare autosomal | 5 |
results demonstrated | 5 |
versus bcg | 5 |
data set | 5 |
leishmania major | 5 |
care system | 5 |
policies due | 5 |
tlr signaling | 5 |
pivotal role | 5 |
paediatric tuberculosis | 5 |
barrier function | 5 |
mycobacterium vaccae | 5 |
different bcg | 5 |
bcg lysate | 5 |
allergic diseases | 5 |
human freedom | 5 |
immunology department | 5 |
recurrent pneumonia | 5 |
pediatric immunology | 5 |
subtilis spores | 5 |
drug discovery | 5 |
reverse transcription | 5 |
malaria incidence | 5 |
previous bcg | 5 |
tlr activation | 5 |
significantly improved | 5 |
urologic cancers | 5 |
strong evidence | 5 |
countries included | 5 |
symptomatic patients | 5 |
strains expressing | 5 |
among different | 5 |
kir genes | 5 |
human respiratory | 5 |
viruses including | 5 |
five patients | 5 |
deaths worldwide | 5 |
intracellular pathogens | 5 |
also used | 5 |
plasma cells | 5 |
immunodeficiency disease | 5 |
mutation affecting | 5 |
intracellular bacterial | 5 |
zero leprosy | 5 |
bacterial infection | 5 |
genetic variation | 5 |
morbidity rates | 5 |
economic status | 5 |
protective antibodies | 5 |
set point | 5 |
retrospective study | 5 |
defining trained | 5 |
mixed effect | 5 |
lactic acid | 5 |
early stage | 5 |
nucleocapsid proteins | 5 |
cognate antigens | 5 |
potential risk | 5 |
administration years | 5 |
bcg childhood | 5 |
newborn mice | 5 |
regulatory cells | 5 |
may exhibit | 5 |
cfr estimates | 5 |
containing protein | 5 |
immunity bcg | 5 |
cer lymph | 5 |
com nrmicro | 5 |
early age | 5 |
angiotensin converting | 5 |
severe pneumonia | 5 |
recent advances | 5 |
vaccine induced | 5 |
plasmid maintenance | 5 |
feline infectious | 5 |
allergic asthma | 5 |
guerin vaccination | 5 |
expression level | 5 |
bcg instillation | 5 |
may affect | 5 |
vaccination rates | 5 |
also resulted | 5 |
cell epitopes | 5 |
regular ivig | 5 |
strong negative | 5 |
connectivity map | 5 |
study shows | 5 |
laboratory investigations | 5 |
treatment delays | 5 |
also shown | 5 |
immune defects | 5 |
population screening | 5 |
inflammatory process | 5 |
cell functions | 5 |
improved protection | 5 |
therapeutic effect | 5 |
tuberculosis incidence | 5 |
eukaryotic expression | 5 |
glycolytic metabolism | 5 |
localized disease | 5 |
study found | 5 |
mass index | 5 |
growth retardation | 5 |
severe complications | 5 |
patients died | 5 |
preliminary report | 5 |
sore throat | 5 |
effect model | 5 |
inducible promoters | 5 |
monocytes macrophages | 5 |
patients developed | 5 |
essential role | 5 |
severe cases | 5 |
clinical improvement | 5 |
adhesion molecule | 5 |
prevent infection | 5 |
unknown etiology | 5 |
recent report | 5 |
myeloid progenitor | 5 |
early childhood | 5 |
wild type | 5 |
attenuated mycobacterium | 5 |
antiviral properties | 5 |
supplementary material | 5 |
cytokines il | 5 |
mtb infection | 5 |
median time | 5 |
operational research | 5 |
possible correlation | 5 |
human studies | 5 |
patients underwent | 5 |
rubella vaccination | 5 |
clinical microbiology | 5 |
term outcomes | 5 |
vulnerable populations | 5 |
time interval | 5 |
using publicly | 5 |
amino acids | 5 |
healthy human | 5 |
expert meeting | 5 |
experimental models | 5 |
pneumonia patients | 5 |
rna virus | 5 |
autoimmune response | 5 |
front immunol | 5 |
positive bacteria | 5 |
localized prostate | 5 |
computed using | 5 |
vaccine provides | 5 |
elderly dependency | 5 |
like influenza | 5 |
regression models | 5 |
phylogenetic analysis | 5 |
ige levels | 5 |
new delhi | 5 |
molecular genetic | 5 |
studies suggested | 5 |
periodic fever | 5 |
hospitalizations per | 5 |
diagnosed leprosy | 5 |
cytokine levels | 5 |
leprae injected | 5 |
ace receptors | 5 |
inactivated vaccine | 5 |
adverse pathologic | 5 |
seven days | 5 |
acute viral | 5 |
fever vaccination | 5 |
first results | 5 |
reducing susceptibility | 5 |
viral challenge | 5 |
data points | 5 |
density lipoprotein | 5 |
gaussian functions | 5 |
vaccine production | 5 |
bordetella pertussis | 5 |
serum igg | 5 |
diagnostic delay | 5 |
medical care | 5 |
antimicrobial properties | 5 |
one million | 5 |
human macrophages | 5 |
cervical cancer | 5 |
coronavirus pandemic | 5 |
may contribute | 5 |
pid registry | 5 |
immunity relevant | 5 |
survival rates | 5 |
viral shedding | 5 |
nature reviews | 5 |
less infections | 5 |
countries date | 5 |
different stages | 5 |
pandemic progression | 5 |
human coronavirus | 5 |
pandemic influenza | 5 |
liver enzymes | 5 |
enhanced immunogenicity | 5 |
specific immune | 5 |
containment measures | 5 |
med doi | 5 |
immune systems | 5 |
variable determining | 5 |
shock proteins | 5 |
long term | 5 |
lombardy region | 5 |
chronic respiratory | 5 |
may act | 5 |
dependent rna | 5 |
measles containing | 5 |
takes advantage | 5 |
following infection | 5 |
routine vaccinations | 5 |
complete genome | 5 |
weight infants | 5 |
rna vaccine | 5 |
conjugate vaccine | 5 |
cystic fibrosis | 5 |
higher number | 5 |
cytoreductive nephrectomy | 5 |
human host | 5 |
successful management | 5 |
primary monocytes | 5 |
promising results | 5 |
vaccination affecting | 5 |
systemic infections | 5 |
clinical evaluation | 5 |
peritoneal macrophages | 5 |
protein sequence | 5 |
bcg draining | 5 |
targeting innate | 5 |
next generation | 5 |
case presentation | 5 |
recombinant lactococcus | 5 |
recommend bcg | 5 |
related systemic | 5 |
fatigue syndrome | 5 |
agents may | 5 |
significantly reduces | 5 |
diagnostic criteria | 5 |
grade disease | 5 |
cytokines including | 5 |
deletion within | 5 |
cumulative number | 5 |
switched memory | 5 |
infectious peritonitis | 5 |
based cohort | 5 |
least squares | 5 |
therapeutic vaccine | 5 |
published data | 5 |
blf displayed | 5 |
infections may | 5 |
differential covid | 5 |
attenuated strains | 5 |
human cells | 5 |
modulatory effects | 5 |
kinase phosphatase | 5 |
global scale | 5 |
genome sequencing | 5 |
ic vaccine | 5 |
dna methylation | 5 |
possible explanation | 5 |
johns hopkins | 5 |
dependency ratio | 5 |
free survival | 5 |
long time | 5 |
data used | 5 |
two deletions | 5 |
analyzed using | 5 |
tuberculosis vaccination | 5 |
antibiotic treatment | 5 |
clinical manifestation | 5 |
average age | 5 |
comparative analysis | 5 |
rates per | 5 |
chadox ncov | 5 |
first wave | 5 |
regarding bcg | 5 |
glycosylation sites | 5 |
immune evasion | 5 |
mice immunized | 5 |
attenuated live | 5 |
delayed type | 5 |
total covid | 5 |
low cost | 5 |
acid bacteria | 5 |
confers protection | 5 |
signal transduction | 5 |
van den | 5 |
infection may | 5 |
infectious episodes | 5 |
matched sibling | 5 |
virus ankara | 5 |
commercially available | 5 |
previous reports | 5 |
enhance innate | 5 |
vaccinia ankara | 5 |
metabolic changes | 5 |
systemic immunity | 5 |
highly enriched | 5 |
known factors | 5 |
categorical variables | 5 |
following exposure | 5 |
higher temperatures | 5 |
pulmonary tuberculosis | 5 |
several reports | 5 |
sequence polymorphisms | 5 |
young group | 5 |
alaska natives | 5 |
vaccination causes | 5 |
bcgosis patients | 5 |
mutations found | 5 |
protein interaction | 5 |
significantly associated | 5 |
proliferative response | 5 |
related morbidity | 5 |
designing mucosal | 5 |
phase trials | 5 |
cd expression | 5 |
statistical methods | 5 |
bowel disease | 5 |
comparative genomics | 5 |
nk cell | 5 |
clostridium difficile | 5 |
multiple linear | 5 |
intravesical treatment | 5 |
effector functions | 5 |
circulating monocytes | 5 |
health expenditure | 5 |
central role | 5 |
chronic bronchitis | 5 |
rb deficiency | 5 |
outcome variable | 5 |
late diagnosis | 5 |
may increase | 5 |
reduce mortality | 5 |
i interferon | 5 |
young children | 5 |
response following | 5 |
possible association | 5 |
three different | 5 |
expressed genes | 5 |
latent tuberculosis | 5 |
chronic mucocutaneous | 5 |
immunoprophylactic agents | 5 |
health agency | 5 |
vaccine policies | 5 |
recently reported | 5 |
antiphospholipid syndrome | 5 |
linear model | 5 |
age distribution | 5 |
statistical computing | 5 |
viral interference | 5 |
significantly different | 5 |
bcg training | 5 |
pathologic outcomes | 5 |
country names | 5 |
girls community | 5 |
neonatal mortality | 5 |
increased tnf | 5 |
gene transcription | 5 |
immunization coverage | 5 |
wide array | 5 |
blood pressure | 5 |
current work | 5 |
treat covid | 5 |
study group | 5 |
animal model | 5 |
ordinary least | 5 |
position paper | 5 |
following immunization | 5 |
evidence suggests | 5 |
hopkins university | 5 |
care units | 5 |
early onset | 5 |
inflammatory bowel | 5 |
genetically modified | 5 |
breast implants | 5 |
cell count | 5 |
initial phase | 5 |
enhanced viral | 5 |
statistical analyses | 5 |
possible mechanism | 5 |
pentose phosphate | 5 |
adult volunteers | 5 |
rapid development | 5 |
bovine milk | 5 |
per country | 5 |
community based | 5 |
health systems | 5 |
particular importance | 5 |
bcg years | 5 |
bcg index | 5 |
surgical intervention | 5 |
study also | 5 |
tetanus toxin | 5 |
heterologous protection | 5 |
single nucleotide | 5 |
component system | 5 |
risk reduction | 5 |
pid cases | 5 |
cell phenotypes | 5 |
new case | 5 |
developed post | 5 |
scid mice | 5 |
skin disease | 5 |
immunization programs | 5 |
systemic infection | 5 |
regulatory role | 5 |
disease among | 5 |
vaccinated individuals | 5 |
dysfunctional immune | 5 |
relative incidence | 5 |
observational study | 5 |
phase study | 5 |
bcg injected | 5 |
policy led | 5 |
induce humoral | 5 |
among adults | 5 |
whole genome | 5 |
virus replication | 5 |
long lasting | 5 |
substantial protection | 5 |
increased expression | 5 |
among contacts | 5 |
sars patients | 5 |
type responses | 5 |
associated lymphoid | 4 |
elderly people | 4 |
whole bcg | 4 |
protect individuals | 4 |
epigenetic mechanisms | 4 |
years post | 4 |
delayed resection | 4 |
sequence analysis | 4 |
home isolation | 4 |
delayed antigen | 4 |
intercellular adhesion | 4 |
infected people | 4 |
kda lipoprotein | 4 |
lung pathology | 4 |
significant protection | 4 |
ongoing bcg | 4 |
new old | 4 |
last two | 4 |
vaccinated children | 4 |
severe infection | 4 |
nontuberculous mycobacteria | 4 |
studies showed | 4 |
may reflect | 4 |
experimental design | 4 |
syndrome characterized | 4 |
medical faculty | 4 |
coronavirus pneumonia | 4 |
short duration | 4 |
tiling array | 4 |
rdrobust stata | 4 |
persian gulf | 4 |
authors thank | 4 |
vaccine adjuvants | 4 |
first group | 4 |
acid cycle | 4 |
critical conditions | 4 |
control cells | 4 |
neoadjuvant chemotherapy | 4 |
positive coefficient | 4 |
genetic diversity | 4 |
existing drugs | 4 |
residual virulence | 4 |
treated patients | 4 |
emerging novel | 4 |
stopped bcg | 4 |
parasitic pathogens | 4 |
bcg status | 4 |
aerosol bcg | 4 |
study predicting | 4 |
approved drugs | 4 |
radiation therapy | 4 |
tumour necrosis | 4 |
blanket approach | 4 |
endothelial cell | 4 |
adults aged | 4 |
educates hematopoietic | 4 |
global covid | 4 |
disease prevention | 4 |
previously reported | 4 |
exact mechanism | 4 |
whole population | 4 |
scientific brief | 4 |
antibodies directed | 4 |
older adults | 4 |
induces long | 4 |
key hub | 4 |
safety concerns | 4 |
national program | 4 |
stopped universal | 4 |
western blotting | 4 |
component regulatory | 4 |
born around | 4 |
mycobacterial loads | 4 |
incomplete kd | 4 |
current study | 4 |
high affinity | 4 |
stopped immunization | 4 |
edged sword | 4 |
will need | 4 |
genomic analysis | 4 |
innate response | 4 |
mice treated | 4 |
mapk phosphorylation | 4 |
brain tissue | 4 |
narrow window | 4 |
reverse transcriptase | 4 |
much less | 4 |
disease characterized | 4 |
approximately one | 4 |
polyarteritis nodosa | 4 |
vectored vaccine | 4 |
monocytes trained | 4 |
immune complex | 4 |
one hundred | 4 |
cell arteritis | 4 |
open access | 4 |
kg dose | 4 |
international union | 4 |
bacterial dna | 4 |
smoking history | 4 |
lower extremities | 4 |
clinical conditions | 4 |
vaccination programmes | 4 |
coronavirus spike | 4 |
better protection | 4 |
hsct bcg | 4 |
response regulator | 4 |
international travel | 4 |
inborn errors | 4 |
serious side | 4 |
irradiated bcg | 4 |
like protease | 4 |
response associated | 4 |
crude covid | 4 |
ethical issues | 4 |
site erythema | 4 |
cell clones | 4 |
nationwide analysis | 4 |
viral spread | 4 |
new tuberculosis | 4 |
smooth muscle | 4 |
increased cd | 4 |
structural proteins | 4 |
dna vaccination | 4 |
mtb antigens | 4 |
pcr test | 4 |
flow cytometric | 4 |
immune effects | 4 |
reviews microbiology | 4 |
kda chaperonin | 4 |
functional responses | 4 |
following stimulation | 4 |
mapks activation | 4 |
mucosal antibodies | 4 |
plasmodium falciparum | 4 |
spread rapidly | 4 |
significant bias | 4 |
attenuated tuberculosis | 4 |
oral vaccination | 4 |
small renal | 4 |
antibody titers | 4 |
coronavirus sars | 4 |
vivo effects | 4 |
molecular weight | 4 |
skin prick | 4 |
exercising caution | 4 |
pulmonary infiltrates | 4 |
antiretroviral drugs | 4 |
patients suffer | 4 |
low birth | 4 |
der heijden | 4 |
bcg educates | 4 |
mainly based | 4 |
mild covid | 4 |
table contains | 4 |
mechanical ventilation | 4 |
mucosal vaccines | 4 |
linked immunosorbent | 4 |
muscleinvasive bladder | 4 |
persistent wheezing | 4 |
genetic background | 4 |
regulatory proteins | 4 |
autoimmune conditions | 4 |
correlation coefficient | 4 |
platelet count | 4 |
bcg disease | 4 |
results indicate | 4 |
generate protective | 4 |
negative bacteria | 4 |
predicted values | 4 |
significant increase | 4 |
kir ds | 4 |
broad spectrum | 4 |
underlying health | 4 |
novel betacoronavirus | 4 |
sirna transfected | 4 |
adverse outcomes | 4 |
transplant disease | 4 |
following yellow | 4 |
containing vaccines | 4 |
bcgosis group | 4 |
current knowledge | 4 |
various mechanisms | 4 |
induced acute | 4 |
exhibit associations | 4 |
lower incidence | 4 |
current status | 4 |
tuberculosis control | 4 |
large proportion | 4 |
universal bacillus | 4 |
cn arm | 4 |
microbial infections | 4 |
survival benefit | 4 |
viral respiratory | 4 |
serum ige | 4 |
autoimmune phenomena | 4 |
affected compared | 4 |
derived macrophages | 4 |
continuous variables | 4 |
crust formation | 4 |
clarivate analytics | 4 |
typhi vaccine | 4 |
vs cells | 4 |
patients undergoing | 4 |
cells may | 4 |
salmonella enteritidis | 4 |
june th | 4 |
individuals aged | 4 |
five weeks | 4 |
ii clinical | 4 |
ng ml | 4 |
oral cancer | 4 |
confounding variables | 4 |
secretion signal | 4 |
key date | 4 |
connecting bcg | 4 |
recent data | 4 |
case increase | 4 |
specific survival | 4 |
disease compared | 4 |
four years | 4 |
cytotoxic lymphocytes | 4 |
past decade | 4 |
low incidence | 4 |
dpm outcome | 4 |
negative control | 4 |
induced mapk | 4 |
antibody production | 4 |
chemokine receptor | 4 |
cells infected | 4 |
american indians | 4 |
atherosclerotic plaque | 4 |
files human | 4 |
underivatised sepharose | 4 |
alternative bcg | 4 |
social contacts | 4 |
hla class | 4 |
detection rate | 4 |
epithelioid cell | 4 |
nucleic acid | 4 |
oligomerization domain | 4 |
listeria infection | 4 |
first days | 4 |
specific antigen | 4 |
following mmr | 4 |
opportunistic pathogen | 4 |
patients reported | 4 |
sars cov | 4 |
stable expression | 4 |
personal protective | 4 |
immunization policy | 4 |
cell immune | 4 |
systemic immunization | 4 |
infection rates | 4 |
medical facilities | 4 |
increased susceptibility | 4 |
igg level | 4 |
confident conclusion | 4 |
following hbv | 4 |
examination findings | 4 |
pandemic across | 4 |
infection rate | 4 |
led us | 4 |
neutrophil influx | 4 |
currently available | 4 |
among indians | 4 |
immune thrombocytopenic | 4 |
stk deficiency | 4 |
healthy children | 4 |
high temperature | 4 |
median follow | 4 |
vaccine steel | 4 |
studies show | 4 |
error term | 4 |
four weeks | 4 |
mycobacterial granulomas | 4 |
one country | 4 |
computed tomography | 4 |
previously vaccinated | 4 |
congenital infections | 4 |
two populations | 4 |
developed bcgosis | 4 |
immunized mice | 4 |
well accepted | 4 |
vaccine will | 4 |
salmonella infections | 4 |
disseminated encephalomyelitis | 4 |
hill criteria | 4 |
leprosy case | 4 |
th century | 4 |
commons license | 4 |
blf decreased | 4 |
homozygous mutation | 4 |
oxygen consumption | 4 |
also considered | 4 |
large cohort | 4 |
glycolytic enzymes | 4 |
lepromatous leprosy | 4 |
new live | 4 |
study reported | 4 |
current policies | 4 |
stat mutation | 4 |
children clinical | 4 |
deprivation therapy | 4 |
many people | 4 |
high grade | 4 |
unvaccinated group | 4 |
several different | 4 |
mycobacterial diseases | 4 |
potential utility | 4 |
recurrent sinopulmonary | 4 |
limited data | 4 |
il rg | 4 |
robust data | 4 |
asymptomatic cases | 4 |
appropriate treatment | 4 |
also possible | 4 |
reproduction numbers | 4 |
increased protection | 4 |
molecule bcg | 4 |
receive bcg | 4 |
recurrent bacterial | 4 |
vaccination protect | 4 |
following nonspecific | 4 |
muscle cells | 4 |
disease outcome | 4 |
expressing ag | 4 |
novel viruses | 4 |
systematic literature | 4 |
protective factor | 4 |
earlier studies | 4 |
two studies | 4 |
lactoferrin lactoferrin | 4 |
colonization factor | 4 |
multiple doses | 4 |
detailed analysis | 4 |
testing rate | 4 |
mg day | 4 |
showed normal | 4 |
respiratory system | 4 |
years follow | 4 |
type immunity | 4 |
lps challenge | 4 |
confounders like | 4 |
study aimed | 4 |
bank data | 4 |
phop promoter | 4 |
number nct | 4 |
viral antigen | 4 |
several hypotheses | 4 |
significantly increased | 4 |
breakage syndrome | 4 |
complement deficiencies | 4 |
lung function | 4 |
untreated units | 4 |
higher morbidity | 4 |
susceptible individuals | 4 |
new clinical | 4 |
supporting evidence | 4 |
disease virus | 4 |
immunosuppressed mice | 4 |
rheumatic diseases | 4 |
skin biopsy | 4 |
breast milk | 4 |
cells expressing | 4 |
unpublished report | 4 |
vaccine initiative | 4 |
per year | 4 |
type infection | 4 |
diagnostic ureteroscopy | 4 |
patient presented | 4 |
full term | 4 |
pandemic restriction | 4 |
stata command | 4 |
vitro evolution | 4 |
unrelated stimuli | 4 |
three patients | 4 |
viruses like | 4 |
merit fc | 4 |
indirect effect | 4 |
also normal | 4 |
safety data | 4 |
potential confounders | 4 |
parental bcg | 4 |
targeted pathogens | 4 |
inhibit sars | 4 |
bcg complications | 4 |
descriptive meta | 4 |
binding oligomerization | 4 |
respiratory illness | 4 |
prevent covid | 4 |
novel deletions | 4 |
manufacturing capacity | 4 |
significant influence | 4 |
study population | 4 |
viral protein | 4 |
antiviral drugs | 4 |
often present | 4 |
autoimmune hepatitis | 4 |
improve protection | 4 |
macrophagic myofasciitis | 4 |
mrna levels | 4 |
pediatric department | 4 |
drug interactions | 4 |
foreign antigens | 4 |
clinical response | 4 |
vaccine mtbvac | 4 |
hong kong | 4 |
experimental animals | 4 |
population age | 4 |
acute disseminated | 4 |
overall survival | 4 |
rare disease | 4 |
united nations | 4 |
mycobacterial cell | 4 |
bcg exposure | 4 |
competing interests | 4 |
received ivig | 4 |
elevated serum | 4 |
lymphocyte count | 4 |
tuberculosis complex | 4 |
lymphocyte subpopulations | 4 |
immunization induces | 4 |
experimental animal | 4 |
soluble mycobacterial | 4 |
great impact | 4 |
supportive therapy | 4 |
pathological findings | 4 |
fatty acids | 4 |
day post | 4 |
local immune | 4 |
commonly used | 4 |
immunization may | 4 |
cause mortality | 4 |
mouse models | 4 |
multiple studies | 4 |
patients following | 4 |
cmap positive | 4 |
prospective study | 4 |
rhode island | 4 |
total deaths | 4 |
since vaccination | 4 |
two data | 4 |
cd counts | 4 |
protect mice | 4 |
protects mice | 4 |
network meta | 4 |
negatively associated | 4 |
viral antigens | 4 |
leprosy protection | 4 |
specific beneficial | 4 |
cell infiltration | 4 |
challenge model | 4 |
study included | 4 |
transgenic mice | 4 |
mammalian target | 4 |
data available | 4 |
mucosal pathogens | 4 |
immunological studies | 4 |
equilibration buffer | 4 |
induced signaling | 4 |
human dendritic | 4 |
cell deficiencies | 4 |
preliminary results | 4 |
glutamine metabolism | 4 |
vaccination provides | 4 |
strong positive | 4 |
best fit | 4 |
body mass | 4 |
interferon gamma | 4 |
hemolytic anemia | 4 |
global partnership | 4 |
convalescent phase | 4 |
demystifying bcg | 4 |
specific intercellular | 4 |
protective innate | 4 |
bcg reduced | 4 |
intraperitoneal route | 4 |
permutation tests | 4 |
structural basis | 4 |
supporting information | 4 |
reducing covid | 4 |
high morbidity | 4 |
asymptomatic patients | 4 |
universal vaccine | 4 |
last five | 4 |
infected mother | 4 |
thrombocytopenic purpura | 4 |
reproduction number | 4 |
viral genome | 4 |
global tuberculosis | 4 |
pathogenic human | 4 |
published studies | 4 |
gdp per | 4 |
intraperitoneal administration | 4 |
lymphocyte populations | 4 |
spectrum anti | 4 |
individual countries | 4 |
isolated human | 4 |
heritable influences | 4 |
normal range | 4 |
well documented | 4 |
groups representing | 4 |
live recombinant | 4 |
phor locus | 4 |
adult pneumococcal | 4 |
vaccines like | 4 |
germ cell | 4 |
pid center | 4 |
mutation leading | 4 |
human milk | 4 |
immunosorbent assay | 4 |
potential vaccine | 4 |
future research | 4 |
human use | 4 |
last decade | 4 |
antiviral immunity | 4 |
small number | 4 |
important factor | 4 |
mucosal tibvs | 4 |
candidate vaccine | 4 |
study period | 4 |
trial participants | 4 |
clinical experience | 4 |
responses elicited | 4 |
study date | 4 |
ulcerative colitis | 4 |
patients compared | 4 |
vector strain | 4 |
mass spectrometry | 4 |
prick test | 4 |
toxoplasma gondii | 4 |
disease outbreak | 4 |
salmonella spp | 4 |
tb disease | 4 |
shigella spp | 4 |
rapid onset | 4 |
tuberculosis cases | 4 |
active tb | 4 |
orally administered | 4 |
low covid | 4 |
old male | 4 |
vaccine repurposing | 4 |
chronic gvhd | 4 |
allowing us | 4 |
known whether | 4 |
another strength | 4 |
modulatory effect | 4 |
enhanced innate | 4 |
herpes virus | 4 |
data regarding | 4 |
research center | 4 |
mast cells | 4 |
type vii | 4 |
antigens may | 4 |
defined syndromes | 4 |
also reduced | 4 |
four novel | 4 |
integral component | 4 |
infect dis | 4 |
mice models | 4 |
infusion rate | 4 |
interaction database | 4 |
iv method | 4 |
vaccine based | 4 |
requiring intensive | 4 |
prospective cohort | 4 |
following heterologous | 4 |
remained significant | 4 |
rd method | 4 |
macrophage enriched | 4 |
studied factor | 4 |
case series | 4 |
improved covid | 4 |
vaccines provide | 4 |
variant histology | 4 |
mycobacterium avium | 4 |
unvaccinated subjects | 4 |
clinical phenotype | 4 |
factors like | 4 |
three cases | 4 |
cell proliferation | 4 |
endemic country | 4 |
reported following | 4 |
children born | 4 |
low level | 4 |
national bacille | 4 |
testing strategy | 4 |
reject fairly | 4 |